๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

PDB10 DIFFERENT PERSISTENCE WITH A BASAL SUPPORTED ORAL THERAPY (BOT) LEADS TO UNEQUAL DISTRIBUTIONS OF INSULIN TREATMENT REGIMENS IN TYPE-2-DIABETICS

โœ Scribed by A Reichelt; M Pfohl; FW Dippel; O Pirk; W Kotowa

Book ID
118612580
Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
82 KB
Volume
12
Category
Article
ISSN
1098-3015

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

PDB54 COMPARISON OF TREATMENT COSTS BETW
PDB54 COMPARISON OF TREATMENT COSTS BETWEEN BASAL-SUPPORTED ORAL THERAPY (BOT) WITH INSULIN GLARGINE (GLA) AND BOT WITH INSULIN DETEMIR (DET) IN PATIENTS WITH TYPE 2 DIABETES (T2D): ECONOMIC EVALUATION BASED ON THE RESULTS OF THE INSULIN GLARGINE (LANTUSยฎ) VERSUS INSULIN DETEMIR (LEVEMIRยฎ) TREAT-TO-TARGET (L2T3) STUDY
โœ PK Schรคdlich; KC Koltermann; FW Dippel; EG Hagenmeyer; B Hรคussler ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 81 KB
Randomized, open-label, parallel-group e
Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: A noninferiority intensification substudy of the DURABLE trial
โœ William F. Miser; Richard Arakaki; Honghua Jiang; Jamie Scism-Bacon; Pamela W. A ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 873 KB